AU · rank #13 · 2026-09-08
FRE
XETRA · EUR · $28.35B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.406 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.05 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +28.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +16.32% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $28.35B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE (FRE) is a German diversified healthcare group operating hospital networks (Helios) and infusion/nutrition therapy (Kabi), generating €22.6B in 2025 revenue.
Rationale
With 91.7% revision agreement across 14 analysts, a 28.4% consensus upside, and 60-day EPS revisions trending positive, the analyst_upside signal is reinforced by genuine fundamental momentum from Fresenius's #FutureFresenius restructuring delivering double-digit EBIT and EPS growth.
Material risks
- 1The -6.68% last earnings surprise signals execution risk against elevated expectations — if the REJUVENATE phase disappoints on margin delivery, the dense analyst consensus (4.5/5 rating, 91.7% agreement) could reverse sharply and compress the 28.4% upside target simultaneously.
- 2High target price dispersion (24.3%) relative to a moderating 2026 growth guide (4–7% organic revenue, 5–10% EPS) suggests analysts disagree materially on terminal value, making the consensus target less reliable as an anchor.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.